{
    "clinical_study": {
        "@rank": "151323", 
        "arm_group": {
            "arm_group_label": "Itraconazole Sequential Therapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of itraconazole sequential\n      therapy (intravenous injection/oral solution) in participants with invasive pulmonary fungal\n      infections ([IPFI]; lung diseases caused by fungal infection)."
        }, 
        "brief_title": "An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Itraconazole 200 milligram (mg) intravenous (directly into the vein) injection was given twice daily for first 2 days and once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily was given for 2 to 4 weeks.", 
                        "title": "Itraconazole Sequential Therapy"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "60"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@lower_limit": "33.34", 
                                            "@upper_limit": "79.45", 
                                            "@value": "55.5"
                                        }
                                    }
                                }
                            }, 
                            "description": "Out of 71 total participants, baseline characteristic (age) was available for only 60 participants who were included in the full analysis set (FAS) population.", 
                            "dispersion": "Full Range", 
                            "param": "Median", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "23"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "37"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "description": "Out of 71 total participants, baseline characteristic (gender) was available for only 60 participants who were included in the full analysis set (FAS) population.", 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Itraconazole 200 milligram (mg) intravenous (directly into the vein) injection was given twice daily for first 2 days and once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily was given for 2 to 4 weeks.", 
                                "title": "Itraconazole Sequential Therapy"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "60"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "8"
                                                    }
                                                }, 
                                                "sub_title": "Cured"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "29"
                                                    }
                                                }, 
                                                "sub_title": "Markedly Improved"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "18"
                                                    }
                                                }, 
                                                "sub_title": "Improved"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }
                                                }, 
                                                "sub_title": "Failed"
                                            }
                                        ]
                                    }, 
                                    "description": "Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Clinical Efficacy", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "The Full analysis set (FAS) population included all participants who received at least 1 intravenous infusion or oral solution of the study drug and completed at least 1 post-baseline visit.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 6", 
                        "title": "Number of Participants With Clinical Efficacy", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Itraconazole 200 milligram (mg) intravenous (directly into the vein) injection was given twice daily for first 2 days and once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily was given for 2 to 4 weeks.", 
                                "title": "Itraconazole Sequential Therapy"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "30"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "20"
                                                    }
                                                }, 
                                                "sub_title": "Fungi cleared"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "10"
                                                    }
                                                }, 
                                                "sub_title": "Fungi not cleared"
                                            }
                                        ]
                                    }, 
                                    "description": "Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Mycological Efficacy", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "The Full analysis set (FAS) population included all participants who received at least 1 intravenous infusion or oral solution of the study drug and completed at least 1 post-baseline visit. Here 'N' signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 6", 
                        "title": "Number of Participants With Mycological Efficacy", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Itraconazole 200 milligram (mg) intravenous (directly into the vein) injection was given twice daily for first 2 days and once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily was given for 2 to 4 weeks.", 
                                "title": "Itraconazole Sequential Therapy"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "60"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "8"
                                                    }
                                                }, 
                                                "sub_title": "Cured"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "32"
                                                    }
                                                }, 
                                                "sub_title": "Markedly Improved"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "16"
                                                    }
                                                }, 
                                                "sub_title": "Improved"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }
                                                }, 
                                                "sub_title": "Failed"
                                            }
                                        ]
                                    }, 
                                    "description": "Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.", 
                                    "param": "Number", 
                                    "title": "Number of Participants With Comprehensive Efficacy", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "The Full analysis set (FAS) population included all participants who received at least 1 intravenous infusion or oral solution of the study drug and completed at least 1 post-baseline visit.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 6", 
                        "title": "Number of Participants With Comprehensive Efficacy", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Itraconazole 200 milligram (mg) intravenous (directly into the vein) injection was given twice daily for first 2 days and once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily was given for 2 to 4 weeks.", 
                        "title": "Itraconazole Sequential Therapy"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "5", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lost to Follow-up"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "5", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lack of Efficacy"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "9", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Physician Decision"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Administered contraindicated medicine"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Transaminase increased more than 3 times"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Drug affected efficacy and safety"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Creatinine clearance<30milliliter/minute"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "71", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "47", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "24", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "xzhou53@163.com", 
                "name_or_title": "Director of Respiratory Department", 
                "organization": "Department of Respiratory Medicine, SHANGHAI First People\u2019s Hospital Affiliated to SHANGHAI JiaoTong University", 
                "phone": "86-21-63071428"
            }, 
            "reported_events": {
                "desc": "Safety set (SS) population (N=61) included all participants who received at least 1 dose of study drug and had safety documents.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Itraconazole 200 milligram (mg) intravenous (directly into the vein) injection was given twice daily for first 2 days and once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily was given for 2 to 4 weeks.", 
                        "title": "Itraconazole Sequential Therapy"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "13", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Granulocytopenia"
                                    }
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Palpitation"
                                    }
                                }, 
                                "title": "Cardiac disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Non-specific anorexia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Diarrhea"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Vomiting"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Night sweating"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Fever"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Abdominal pain"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Septic shock"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Headache"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Hyperbilirubinemia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Hepatic function abnormal"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "GPT increased"
                                        }
                                    ]
                                }, 
                                "title": "Hepatobiliary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "3", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Hypokalaemia"
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Dizziness"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Tremor"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Urinary tract infection"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Renal function abnormal"
                                        }
                                    ]
                                }, 
                                "title": "Renal and urinary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Hemoptysis"
                                    }
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Dermatoses"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Rash"
                                        }
                                    ]
                                }, 
                                "title": "Skin and subcutaneous tissue disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "No coding system", 
                    "frequency_threshold": "0"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "4", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Edema"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "61"
                                            }, 
                                            "sub_title": "Death"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Fungal infection"
                                    }
                                }, 
                                "title": "Immune system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "61"
                                        }, 
                                        "sub_title": "Hemoptysis"
                                    }
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "No coding system"
                }, 
                "time_frame": "From the signing of informed consent until end of the study (week 6)."
            }
        }, 
        "completion_date": {
            "#text": "January 2009", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Fungal Infection", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases, Fungal", 
                "Mycoses"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), single arm,\n      multicenter (when more than one hospital or medical school team work on a medical research\n      study) study to evaluate the efficacy and safety of itraconazole sequential therapy in\n      participants with IPFI. The study duration will be 4 to 6 weeks. The treatment will be\n      divided into the intravenous (into a vein) injection period and the oral solution\n      administration (giving) period. During the intravenous injection period 200 milligram (mg)\n      twice daily loading dose (large initial dose) will be given for first 2 days, 200 mg once\n      daily for the subsequent 12 days. Then sequential itraconazole oral solution 200 mg twice\n      daily will be given as maintenance therapy (treatment designed to help the original primary\n      treatment to succeed) for 2-4 weeks. Participant's clinical, mycological and comprehensive\n      efficacy will be assessed at Week 6. Participants' safety will be monitored throughout the\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Probable or proven invasive pulmonary infectious participants (IPFI) - Hospitalized\n             participants (at least hospitalized treatment and observation could be ensured during\n             the intravenous injection period) - The participants (or legal representatives) have\n             signed the informed consent forms.\n\n        Exclusion Criteria:\n\n          -  Currently taking taboo drugs, such as terfenadine, astemizole, cisapride and HMG CoA\n             reductase inhibitors (for example simvastatin, lovastatin, oral or intravenous\n             midazolam or triazolam) - History of allergy or intolerance to imidazoles or pyrrole\n             drugs (for example fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole)\n             -  Pregnant and breast feeding women, or women of child bearing age not taking\n             effective contraception measures - Participants with pure oral, urinary tract, and\n             vaginal candidiasis (yeast infection) - Participants with fungal meningitis\n             (inflammation of the meninges), active liver disease, renal insufficiency with the\n             serum creatinine clearance rate less than 30 milliliter per minute (ml/min), and\n             current abnormal cardiac function such as congestive heart failure (condition in\n             which the heart is unable to pump out sufficient blood to meet the metabolic need of\n             the body), or participants with history of congestive heart failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "71", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "firstreceived_results_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823289", 
            "org_study_id": "CR014362", 
            "secondary_id": [
                "ITRFUN4025", 
                "SPOIV-CHN-MA-04"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Itraconazole Sequential Therapy", 
            "description": "Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.", 
            "intervention_name": "Itraconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Invasive Pulmonary Fungal Infection", 
            "Itraconazole"
        ], 
        "lastchanged_date": "April 12, 2013", 
        "number_of_arms": "1", 
        "official_title": "Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections", 
        "overall_official": {
            "affiliation": "Xian-Janssen Pharmaceutical Ltd.", 
            "last_name": "Xian-Janssen Pharmaceutical Ltd., China Clinical trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee/IRB", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.", 
                "measure": "Number of Participants With Clinical Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "description": "Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.", 
                "measure": "Number of Participants With Mycological Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "description": "Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.", 
                "measure": "Number of Participants With Comprehensive Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823289"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Xian-Janssen Pharmaceutical Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xian-Janssen Pharmaceutical Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2007", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}